Adherence to hepatitis C virus therapy and early virologic outcomes. - Wikidata - wikimedia - TriplyDB

Adherence to hepatitis C virus therapy and early virologic outcomes.

Adherence to hepatitis C virus therapy and early virologic outcomes.

http://www.wikidata.org/entity/Q37157715

about

The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents Self-efficacy and adherence to antiviral treatment for chronic hepatitis C.Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection.Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study.Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients.Evaluation of the significance of pretreatment liver biopsy and baseline mental health disorder diagnosis on hepatitis C treatment completion rates at a veterans affairs medical center.Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response.Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence.Adherence in liver transplant recipients.IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.Impact of alcohol consumption among patients in hepatitis C virus treatment.Recommendations for the management of hepatitis C virus infection among people who inject drugs.The efficacy and safety of treating hepatitis C in patients with a diagnosis of schizophrenia.Recommendations for the management of hepatitis C virus infection among people who inject drugs.Towards HCV extinction with modern HCV treatment? "Yes we can!".Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible.Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.Patient preferences and assessment of likely adherence to hepatitis C virus treatment.Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study.Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases.

P2860

Q27491355-97A0589E-F7D6-4C78-9537-9E8A8C03BA3E Q30365599-8B0F5B10-C01D-4057-8785-1B2E009E3C57 Q33774344-BDB5F2A5-95FA-49FD-A68E-C06BD391F057 Q34736149-4F747BF1-6EE9-4CF4-9D4F-95E8B9DE12D7 Q35008754-E81258E1-DA28-4283-A4D6-4EDBBA752C41 Q35053344-91BD12E6-2562-4F9F-A7A5-8B97B53EBA86 Q36006322-66BEBAC1-B6DF-4AB1-A063-640E69AFC58F Q36418455-E19351BC-2E6C-47DA-9287-F1369E6492A2 Q36445942-88213610-2DCE-4823-A641-4EAB8669E7F1 Q36896324-B1C5D931-0DC6-4A10-A457-15AF29CC4F19 Q36955116-925C916E-0B65-4DA9-9751-87A4E3DE3332 Q36990416-1AFAAD11-A139-463B-A404-7247EFC57D30 Q37850768-F1070AA0-3C1C-460D-8EDF-B4820FC05064 Q38053543-3EDDED5B-420C-4E1C-AD83-EB7EBCF853A2 Q40116427-226111A0-9292-434F-A76A-6722F54AB4A8 Q41047662-88725BEB-D409-4A57-ACAB-C979234A85F0 Q42236591-8BE8F78A-6F26-4B16-BF71-55A1E47237ED Q42280296-7A7C48BE-4B51-4400-AFC4-6EC83AE2A4A9 Q42345774-6ACD3040-F89C-48D0-8AA2-9A300008F77D Q42604420-FDAD29B5-2944-4F45-B1F8-E2B3FD0914B8 Q42992590-C9BF866E-4041-4586-8591-A073876AFEE3 Q42998032-6438747B-6F33-45D1-A6CB-78C785A4DE5F Q46546968-BEC5B64E-8082-46F5-98CC-EBE885EA2347 Q47325212-3BDE2327-0D84-4D93-9BA0-035B25004343

P2860

Adherence to hepatitis C virus therapy and early virologic outcomes.

http://www.wikidata.org/entity/Q37157715

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Adherence to hepatitis C virus therapy and early virologic outcomes.

@en

Adherence to hepatitis C virus therapy and early virologic outcomes.

@nl

type

label

Adherence to hepatitis C virus therapy and early virologic outcomes.

@en

Adherence to hepatitis C virus therapy and early virologic outcomes.

@nl

prefLabel

Adherence to hepatitis C virus therapy and early virologic outcomes.

@en

Adherence to hepatitis C virus therapy and early virologic outcomes.

@nl

P1433

Q37157715-44EB856D-F819-4FCC-9178-8DCA1B7488DD

P1476

Q37157715-7D90A029-E64E-4156-AC0E-9A02E9D717DD

P2093

Q37157715-423CA5A4-81A2-41B4-8E63-E9A3D7B61922

Q37157715-4B8C3A2F-95B0-4F12-A214-668EAAC0CB66

Q37157715-813688DD-D3A5-4F3D-BBB5-246DDB27E354

Q37157715-8E13CE47-8D92-405B-91D8-72F2B5C1E6D7

Q37157715-9BB72CF9-0C06-4A6C-BB9C-68A16873E390

Q37157715-A73721EB-B5AA-48B7-BFF8-8A9830DBFA41

Q37157715-C68C2CD1-AA33-43F2-A1FA-189972CBDF36

Q37157715-DDE3C510-4BBA-47BC-8DC6-553539D65B04

P2860

Q37157715-166679EB-4B78-4386-8A48-385318754A86

Q37157715-2896F160-AB44-4CCA-89EE-7D671A69F0A9

Q37157715-35625511-9B09-424A-963E-33E4B3A9B9B5

Q37157715-35C6E731-C19A-43B9-A6B1-D6B434180EE9

Q37157715-36FF6E2C-F934-4492-BCAB-400902717B41

Q37157715-5492EB99-1E0C-43DD-BE1E-BF3DAF58054F

Q37157715-6DB12D37-1338-41F3-8B09-FF2EE7F8D4FB

Q37157715-83166F8D-3995-4CE1-8C09-9A2FA389A4DC

Q37157715-8C7CF519-5998-458B-B5D1-088A5EB1144C

Q37157715-A1312CE8-5DFE-4B1F-9BF5-90498A9EA897

P304

Q37157715-E884C456-BE25-4AC3-AD1C-1D61BF688892

P31

Q37157715-EE29AE91-1B97-440B-9626-1CECE1CC8607

P356

Q37157715-5453B358-BA93-47BA-89A4-BE50CED06614

P407

Q37157715-DC239F35-4ADA-4966-9413-2FFED177D02A

P433

Q37157715-5AC51559-0C0B-469C-B87D-97DF13B61A39

P478

Q37157715-89CB3046-C874-4CD5-9964-C3C2412B1806

P577

Q37157715-7A265915-051B-418A-81A0-1FE5A3C9B61D

P5875

Q37157715-F213C46E-7D6E-4692-9D36-9775FD9E865E

P698

Q37157715-3050D191-8607-4083-84D7-D57738544427

P921

Q37157715-3A4F2171-14B9-4269-9CD3-31EE0944E889

P932

Q37157715-C00FE79C-DEA0-45C3-A32D-665971AD360D

P356

P1433

Clinical Infectious Diseases

P1476

Adherence to hepatitis C virus therapy and early virologic outcomes.

@en

P2093

A Russell Localio

http://www.w3.org/2001/XMLSchema#string

Jay R Kostman

http://www.w3.org/2001/XMLSchema#string

Robert Gross

http://www.w3.org/2001/XMLSchema#string

Rose O'Flynn

http://www.w3.org/2001/XMLSchema#string

Valerianna K Amorosa

http://www.w3.org/2001/XMLSchema#string

Valerie Teal

http://www.w3.org/2001/XMLSchema#string

Vincent Lo Re

http://www.w3.org/2001/XMLSchema#string

Zachariah Dorey-Stein

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Diagnosis, management, and treatment of hepatitis C

Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data.

The assessment of refill compliance using pharmacy records: methods, validity, and applications.

The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients.

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.

P304

186-193

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/595685

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23667901

http://www.w3.org/2001/XMLSchema#string

P698

19086908

http://www.w3.org/2001/XMLSchema#string

P921

P932

2668718

http://www.w3.org/2001/XMLSchema#string